Literature DB >> 28073973

Human foetal ovary shares meiotic preventing factors with the developing testis.

Nelly Frydman1,2, Marine Poulain3, Brahim Arkoun3, Clotilde Duquenne3, Sophie Tourpin3, Sébastien Messiaen3, René Habert3, Virginie Rouiller-Fabre3, Alexandra Benachi4, Gabriel Livera3.   

Abstract

STUDY QUESTION: How can pre-meiotic germ cells persist in the human foetal ovary? SUMMARY ANSWER: Numerous oogonia escaping meiotic entry were retrieved throughout human ovarian development simultaneously with the expression of signalling pathways preventing meiosis, typically described in the rodent embryonic testis. WHAT IS KNOWN ALREADY: The transition from mitosis to meiosis is a key event in female germ cells that remains poorly documented in research on the human ovary. Previous reports described a strikingly asynchronous differentiation in the human female germ line during development, with the persistence of oogonia among oocytes and follicles during the second and third trimesters. The possible mechanisms allowing some cells to escape meiosis remain elusive. STUDY DESIGN SIZE, DURATION: In order to document the extent of this phenomenon, we detailed the expression profile of germ cell differentiation markers using 73 ovaries ranging from 6.4 to 35 weeks post-fertilization. PARTICIPANTS/MATERIALS SETTING,
METHODS: Pre-meiotic markers were detected by immunohistochemistry or qRT-PCR. The expression of the main meiosis-preventing factors identified in mice was analysed, and their functionality assessed using organ cultures. MAIN RESULTS AND THE ROLE OF CHANCE: Oogonia stained for AP2γ could be traced from the first trimester until the end of the third trimester. Female germ cell differentiation is organized both in time and space in a centripetal manner in the foetal human ovary. Unexpectedly, some features usually ascribed to rodent pre-spermatogonia could be observed in human foetal ovaries, such as NANOS2 expression and quiescence in some germ cells. The two main somatic signals known to inhibit meiosis in the mouse embryonic testis, CYP26B1 and FGF9, were detected in the human ovary and act simultaneously to repress STRA8 and meiosis in human foetal female germ cells. LARGE SCALE DATA: N/A. LIMITATIONS REASON FOR CAUTION: Our conclusions relied partly on in vitro experiments. Germ cells were not systematically identified with immunostaining and some may have thus escaped analysis. WIDER IMPLICATIONS OF THE
FINDINGS: We found evidence that a robust repression of meiotic entry is taking place in the human foetal ovary, possibly explaining the exceptional long-lasting presence of pre-meiotic germ cells until late gestational age. This result calls for a redefinition of the markers known as classical male markers, which may in fact characterize mammalian developing gonads irrespectively of their sex. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by the Université Paris Diderot-Paris 7 and Université Paris-Sud, CEA, INSERM, and Agence de la Biomédecine. The authors declare no conflict of interest.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  AP2γ; CYP26B1; FGF9; gonad differentiation; human foetal ovary; meiosis; oogonia

Mesh:

Year:  2017        PMID: 28073973     DOI: 10.1093/humrep/dew343

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

Review 1.  Deciphering Sex-Specific Differentiation of Human Fetal Gonads: Insight From Experimental Models.

Authors:  Malene Lundgaard Riis; Anne Jørgensen
Journal:  Front Cell Dev Biol       Date:  2022-06-02

2.  A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency.

Authors:  Baptiste Fouquet; Patrycja Pawlikowska; Reiner A Veitia; Micheline Misrahi; Sandrine Caburet; Celine Guigon; Marika Mäkinen; Laura Tanner; Marja Hietala; Kaja Urbanska; Laura Bellutti; Bérangère Legois; Bettina Bessieres; Alain Gougeon; Alexandra Benachi; Gabriel Livera; Filippo Rosselli
Journal:  Elife       Date:  2017-12-12       Impact factor: 8.140

3.  Divergent Roles of CYP26B1 and Endogenous Retinoic Acid in Mouse Fetal Gonads.

Authors:  Laura Bellutti; Emilie Abby; Sophie Tourpin; Sébastien Messiaen; Delphine Moison; Emilie Trautmann; Marie-Justine Guerquin; Virginie Rouiller-Fabre; René Habert; Gabriel Livera
Journal:  Biomolecules       Date:  2019-09-26

4.  Dysregulation of FGFR signalling by a selective inhibitor reduces germ cell survival in human fetal gonads of both sexes and alters the somatic niche in fetal testes.

Authors:  K Harpelunde Poulsen; J E Nielsen; H Frederiksen; C Melau; K Juul Hare; L Langhoff Thuesen; S Perlman; L Lundvall; R T Mitchell; A Juul; E Rajpert-De Meyts; A Jørgensen
Journal:  Hum Reprod       Date:  2019-11-01       Impact factor: 6.918

Review 5.  Putative adverse outcome pathways for female reproductive disorders to improve testing and regulation of chemicals.

Authors:  Hanna K L Johansson; Pauliina Damdimopoulou; Majorie B M van Duursen; Julie Boberg; Delphine Franssen; Marijke de Cock; Kersti Jääger; Magdalena Wagner; Agne Velthut-Meikas; Yuling Xie; Lisa Connolly; Pauline Lelandais; Severine Mazaud-Guittot; Andres Salumets; Monica Kam Draskau; Panagiotis Filis; Paul A Fowler; Sofie Christiansen; Anne-Simone Parent; Terje Svingen
Journal:  Arch Toxicol       Date:  2020-07-07       Impact factor: 5.153

6.  Reduced retinoic acid synthesis accelerates prophase I and follicle activation.

Authors:  Roseanne Rosario; Hazel L Stewart; Emily Walshe; Richard A Anderson
Journal:  Reproduction       Date:  2020-09       Impact factor: 3.906

Review 7.  RNA-binding proteins in human oogenesis: Balancing differentiation and self-renewal in the female fetal germline.

Authors:  Roseanne Rosario; Andrew J Childs; Richard A Anderson
Journal:  Stem Cell Res       Date:  2017-04-18       Impact factor: 2.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.